Jaejoon Lee is an application scientist in Pall Biotech responsible for supporting customers to implement Pall technologies and product in downstream manufacturing process. He made his career in biopharmaceutical industry spending 7 years on process development and process characterization of vaccine in GC Pharma. In March 2019, He joined Pall Biotech taking in charge of a technical support to our customer especially in early-stage development and field support.
Daniel Galbraith, Ph.D.,
Dr. Minkyung Kim, PharmD, MBA, MSc
Dr. Minkyung Kim is a scientific affairs manager at USP, APAC. She holds her licenses as a registered pharmacist in the state of Pennsylvania and South Korea. Kim leads global cell and gene landscaping projects to identify opportunities and challenges for product development; distinguish global, regional, and local key opinion leaders; and create a network for further collaboration. Before joining the USP, she worked at Mundipharma and Bayer in Medical Affairs, where she led advisory board meetings for immunology and oncology products and deployed diagnostic validating platforms for various companion diagnostics. Her work experience also includes research at the National Cancer Center in South Korea.
Jun Park, Ph.D.,
Jae Young Yang
Sung Ho Hahm
Jong Hyuk Lim
Kyung Jin Lee
Kee Chan Ahn
Vickram has completed his Masters in Supply Chain Management from SP Jain Institute of Management and has 17+ years of experience in Logistics, Heavy Engineering and Life Science Industries across South East Asia, Middle East & India. He has occupied positions in Supply Chain Planning, Supply Chain Execution and Product Management at various times. Vickram is described as a ‘go-getter’ and recognized as a thought leader in Supply Chain Practice. He is known for marrying Supply Chain Concepts and Practice in the pursuit of excellence. He was recently recognized as a Supply Chain Super Achiever(40-under-40) by Celerity in the Healthcare sector. Vickram currently leads the Planning function – Global Supply Chain at Sunpharma. Sun is India’s largest and one of world’s leading generic pharmaceutical & API manufacturer with multiple production facilities spread across 3 continents and sales footprint across 100+ countries.
Courtney Soulsby works as a Sector Director for the Healthcare and Life Sciences sector team for BSI (British Standards Institution). Working to understanding market challenges and future needs of the healthcare sector, Courtney works with key clients and industry partners to develop holistic solutions, strategies and programs. Courtney has worked with pharmaceutical industry and their downstream logistics supply chain for over ten years – with a deep understanding the issues with regulation, compliance, quality, and other risk exposures when transporting medicines.
Bonghee Lee, DVM, PhD
Jae Hoon Ko
Chae-Ok, Yun, Ph.D
Soo Young Choi, PhD
Antonio Lee Ph.D
Dr. Yu Zhang
Jaeho Jung, Ph.D,
WonHyun Hwang (James Hwang)
Jooyoun Alice Lee
Alan Kennedy is a specialist in supply chain dynamics who, with his extensive cross-sector experience, is focused on bringing best-collaboration practice to pharma-logistics. He is the founder and Executive Director of Pharma TEAM-UP, a non-profit initiative with the goal of fostering closer supply chain integration and he is one of the principal architects behind the Poseidon program, a new logistics delivery model that has been conceived to radically transform the transportation of pharmaceutical products by sea. This is being achieved through the application of contemporary supply chain best-practice and structured, multi-party collaboration. He regularly presents on this topic and has authored numerous papers.
Linda Kim has performed a variety of key roles such as establishing pharma cold chain logistics services, cold chain management training, sales & marketing, and Korea branch set-up in global leading life science logistics companies including Marken, World Courier, and TNT. After working as the first Korean Country General Manager of Marken, Linda founded Cold Chain Platform (CCP). By sharing international cold chain logistics information for the pharma industry and facilitating access to cold chain solutions and trends, Linda helps people by connecting cold chain solution providers and users. Linda received a BA from Sookmyung Women’s University and an MBA in Logistics Management from Inha University, Korea.
Heesoon Chang, Ph.D., MBA
HeeSoon is the CEO of Orgenesis Korea with a Doctorate of Philosophy in Medical Science from Yonsei University and MBA from Korea University. Her post-doctorate research experience has brought her through University of Pennsylvania, Harvard Medical School and University of Southern California.
Before joining Orgenesis Korea, HeeSoon worked as the Regional Team Leader at Kimberly-Clark, CEO of Curogene Life Sciences, and CSO of Vaxcell-Bio. She has both the technical skills and qualification through her broad and extensive academic educations and working experience within the pharmaceutical industry.
Yongjun (Leo) Choi
Jin-San Yoo, Dr. rer. nat. Diplom Biol.,
Dr. Jin-San Yoo is CEO, President and Founder of PharmAbcine, a clinical
stage public company developing innovative oncology drugs. He has >20 years’ experience in the BioPharma industries. He is an acting expert at the MAB working group of EDQM for 5 years. He is the acting advisory board of policy making of MFDS and he served as an expert of the central evaluation committee of MFDS.
Dr. Yoo has authored numerous papers in peer reviewed journals, book chapters and he is also an inventor of several patents and patent applications.
Seong-Wook Lee, Ph.D.
Dr. Lee found Rznomics Inc., RNA-based biopharmaceutical company, in 2017 and has served as President and CEO. Dr. Lee is also currently a full Professor at Dankook University in Korea since 1997. He received the B.Sc. and M.Sc. degrees in Dept. of Microbiology from Seoul National University and obtained Ph.D. degree in Dept. of Molecular Biology at Cornell University. He was working as a graduate research assistant in Memorial Sloan-Kettering Cancer Center and as a research associate and a visiting scholar in Duke University Medical Center. His areas of expertise include development of RNAs as gene therapeutics as well as diagnostics. Especially, he has focused on developing RNAs for the treatment and prevention of diverse intractable diseases including genetic, infectious, degenerative, and malignant diseases. He serves now as an editorial board member of renowned international journals especially in the field of nucleic acid gene therapy including ‘Nucleic Acid Therapeutics’ and ‘Molecular Therapy-Nucleic Acid’. He served as President of ‘Korean Society of Gene and Cell Therapy’.
The East Asia region is making great progress in developing cell and gene therapy to address and bring hope to the high unmet medical needs. As part of the new wave of advanced therapy medicinal product (ATMP), cell and gene therapy biopharmas in the East Asia region has contributed extensive capital investment in research & development of novel therapeutic agents, setting state-of-art manufacturing plants while collaborations are formed between multinational companies to accelerate the progress and developments of cell and gene therapy industry. Growing at a compound growth rate of above 14%, the cell and gene therapy market in East Asia is expected to reach USD 2.9 billion by 2028. Among the countries, China, Korea, Japan and Taiwan showed exceptional achievements in R&D of cell & gene therapy products and offered great potential for treatment of various diseases.
In this edition of Cell and Gene Therapy World East Asia, key opinion leaders from major key players in the East Asia region industry come together to discuss carefully researched content to address the challenges and explore opportunities of CAR-T/NK products manufacturing, technologies to develop cell and gene therapy products, best practices of clinical trials, case studies and more. This is the one and only Cell and Gene Therapy conference to help explore collaboration and partnership opportunities in the East Asia region to address life-saving medicine.
The pace of activity in cell and gene therapy has not been affected by the massive disruption of COVID-19. Instead, it shows accelerated performance in the past years. More than 50 products worth over USD 16 billion have been licensed and not to mention the total financing of regenerative medicine has doubled to $20 billion which shows a 50% increase from the year before. Despite the attention given to cell and gene therapy, hurdles are obvious in the sense of unclear regulatory guidelines and standards, lack of manufacturing capacity and challenges in clinical trial site management.
To address these issues, C-levels, Directors, Heads of cell and gene therapy from leading biopharma in East Asia region come under one roof to discuss and debate the best practices of clinical trials of CAR-T products, advances in cell and gene therapy manufacturing, case studies and success stories sharing, regulatory updates for the purpose of leading cell and gene therapy excellence in the market.
Clinical Trials of CAR-T Products from East Asia
Novel therapies undergo extensive studies and trials which can be incredibly difficult. Pain points within the current clinical framework of developments for cell and gene therapy due to the rapid pace of the industry will be discussed on top with solutions and sharing by regulators to address the requirements and guidelines for optimizing clinical trials outcome.
Advances in Cell & Gene Therapy Manufacturing
Explore the showcase and debate session about the latest breakthroughs in advancing engineering and large scale manufacturing of next generation therapies from the key opinion leaders.
Scale Out Strategies & Cost Optimization for Cell & Gene Therapy
Exciting topics and sharing on how to tackle the issue of costs in cell and gene therapy manufacturing through effective plant design optimization, platform approach and process optimization for a shorter timeline to market and commercialization.
Cell & Gene Therapy Case Studies from East Asia Region
Listen from the emerging biopharma about their success stories sharing through case studies to replicate the formulas and strategies for effective planning and implementation of novel therapies manufacturing.
Advances in CAR-T/NK Cell Manufacturing
From core capabilities including cell line development, process development, analytical method development, find out how to achieve faster and better path to IND filings and successful BLAs with the support from CMO/CDMO.
Regulatory Considerations and ATMPs Updates
Despite the advances of cell and gene therapy, they are still considered as a relatively new form of therapy and hence the regulatory approval, guidelines and documentation for filing are struggling to keep up with the fast pace of the industry. We have experts from the regulatory sector to lead you through the latest frameworks and keep you updated!
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development, and production activities in the industries we serve. One of our greatest strengths comes from having a global infrastructure that is strategically located to support the needs of our customers. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world.
Merck, a life science leader, is a business of Merck KGaA, Darmstadt, Germany. Our products and services help you safely and efficiently develop and manufacture therapeutics.
Our BioReliance® Biosafety Testing Services offer comprehensive and integrated services that support every phase of the testing, development and manufacturing process.
Your Therapy, Our Priority
Visit our Merck booth.
Speak to us, and learn more:
한국후지쯔는 글로벌 기업인 마스터콘트롤사의 QMS(Quality Management Solutions)를 한국에서 독점, 제공하고 있습니다. 마스터콘트롤의 QMS는 미국 식품의약국 FDA를 포함해 규제기관을 비롯해 전 세계 약 1000개사 이상 고객이 도입하여 사용하고 있습니다. 마스터콘트롤사의 통합 품질경영 솔루션 (QMS)은 각종 기준서와 절차서의 관리를 위한 EDMS(Electronic Document Management System)를 기본으로 LMS(Learning Management System), Deviation, CAPA, Equipment Mainteanace, EBR 뿐만 아니라 Audit과 Supplier관리를 위해 통합된 모듈을 제공합니다.
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of lifesaving and life-enhancing medicines for patients. With almost 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 40 billion components and devices each year.
Headquartered in Exton, Pennsylvania, and in business for nearly a century, West in its fiscal year 2020 generated over $2.147 billion in annual revenue. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.
For over 200 years, USP has worked to build trust where it matters most: in the world's medicines, dietary supplements and foods. Through our rigorous science and the public quality standards we set, USP helps protect patient safety and improve the health of people around the world. USP is an independent, scientific nonprofit organization focused on building trust in the supply of safe, quality medicines. We are working to strengthen the global supply chain so that the medicines people rely on for health are available when needed and work as expected.
Pall Corporation provides critical filtration, separation, and purification solutions to meet the demanding needs of a broad spectrum of life sciences and industrial customers around the globe. Across 80 locations and 10,000 people worldwide, we are unified by a singular drive: to solve our customers' biggest fluid management challenges. And in doing so advance health, safety, and environmentally responsible technologies. Together, our Life Sciences and Industrial teams serve a diverse range of customers including biotechnology, pharmaceutical, medical, food and beverage, laboratory, microelectronics, aerospace, fuels, petrochemical, chemical, automotive and power generation industries. Our industry-leading technologies and solutions are at work in countless applications, protecting critical operating assets, improving product quality, safeguarding the health, and minimizing emissions and waste
For more info, please check: https://www.pall.com/en/biotech.html
Emerson is where technology and engineering come together to create solutions for the benefit of our customers, driven without compromise for a world in action. As a global innovator, Emerson has a deep legacy of solving the most complex challenges facing modern life. We combine advanced technologies, industry-leading expertise and an insatiable curiosity about the world around us to create sustainable solutions for the essential customers we serve.
Our how is complex, but our why is simple and found in our unified global Purpose: We drive innovation that makes the world healthier, safer, smarter and more sustainable. https://www.emerson.com/en-sg/
Yourway is the only truly integrated premium courier and clinical packager, offering — along with our comprehensive transport capabilities — primary and secondary pharmaceutical packaging services, warehousing, and distribution support, including temperature-controlled solutions, unused product return services, including product destruction, and assistance with logistics project management. The latter services include sourcing of comparator drugs and other supplies, establishing optimal delivery strategies across global trials, documentation support and the provision of regulatory advice regarding country-specific requirements. Our team of specialists is highly experienced in supporting clients’ needs for the execution of phase I, II, III and IV clinical trials. With all logistics needs for clinical trials easily obtained in one place, outsourcing to, or managing relationships with multiple organizations is no longer necessary.
Yokogawa provides advanced solutions in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, and food. Yokogawa addresses customer issues regarding the optimization of production, assets, and the supply chain with the effective application of digital technologies, enabling the transition to autonomous operations. Founded in Tokyo in 1915, Yokogawa continues to work toward a sustainable society through its 17,500 employees in a global network of 119 companies spanning 61 countries.
Life business is one of our key contributed area over 30 years with our vision to lead the world in advancing Bio Industrial Autonomy and contribute to a future embracing global harmony with the aim of clarifying future developments of the business, its scope and direction.
Yokogawa는 에너지, 화학, 재료, 제약, 식품 등 다양한 산업의 고객사에게 계측, 제어, 정보 분야의 첨단 솔루션을 제공하고 있다. Yokogawa는 효과적인 디지털 기술 응용 프로그램을 통해 생산 최적화, 자산, 공급망과 관련된 고객사의 문제를 해결하고 자율화된 운영으로의 전환을 지원한다. 1915년 도쿄에 설립된 Yokogawa는 세계 61개국, 119개 기업으로 이뤄진 글로벌 네트워크에서 일하는 1만 7500명의 직원과 더불어 지속 가능한 사회를 구현하기 위해 노력하고 있다.
Yokogawa의 비전인 Bio Industrial Autonomy의 발전에 세계를 선도하고 사업의 미래 발전을 명확히 하는 것을 목표로 미래의 글로벌 화합에 공헌을 실현하기 위해 30년 이상 Life Business를 핵심 투자 분야로 분류하여 왔습니다.
By leveraging FUJIFILM Group’s collective bio-related technologies, including Wako Pure Chemical and Irvine Scientific, FUJIFILM continues to accelerate the growth and provide broad product portfolio in bio-medical through synergies and collaborations.
With over 45 years of industry experience, FUJIFILM Irvine Scientific (FISI) is a worldwide leader in the innovation and manufacture of cell culture media. FISI offers a diverse portfolio of advanced cell culture media solutions including high-performance, proprietary chemically-defined media, rapid media screening and optimization services.
FUJIFILM Wako Pure Chemical (FFWK) is a world leading supplier of high purity chemicals and reagents based in Japan. FFWK has broad product lines, from various raw materials to QC/QA testing products, in its Laboratory chemicals to precisely meet various needs in all fields of study.
Please click the link below.
Since 1997, CHAYON Laboratories Inc. has been introducing the latest technologies and products for life sciences and other related research areas. With its 25 years of service experience and professional knowledge, CHAYON continues to evolve in the rapidly changing field along with the leading scientists and researchers.
Based on the decades of systematic support by our in-house Technical Sales & Application Scientists, CHAYON is focused on providing unrivaled drug development/discovery services in the Drug Discovery area. In addition, CHAYON is leading the market in various research fields by supplying most up-to-date molecular and cell biology related products, as well as pre-clinical imaging and other automation equipment that incorporate the latest technologies.
Aside from the scientific support and its product portfolio, CHAYON is also known for providing preeminent customer satisfaction in all cases and projects; utilizing its own global standard distribution center for systematic logistics, and field support with internationally trained in-house service engineers.
Finding new possibilities and discovering the future is the value pursued by CHAYON for many years, and we believe that value may only become tangible by the hands of researchers. CHAYON Laboratories will be with researchers to realize our value and their mission.
Everything began with a commitment to serve the life sciences and healthcare industries by offering global transport and innovative temperature-controlled logistics solutions. Being one of the market leaders in our sector and dedicated to the clinical trial and cell & gene therapy communities, we are operating in more than 150 countries intending to improve the health of people around the world. Truly focused on our customer and patient needs, we, through a dedicated team, plan, manage and implement a tailor-made temperature-controlled solution to fit your requirements and business goals.
Count on us to deliver your life-saving goods worldwide - Count on CRYOPDP!
Thermo Fisher Scientific, Pharma Services (Patheon)
Thermo Fisher Scientific provides industry-leading pharma services solutions for drug development, clinical trial logistics and commercial manufacturing to customers through our Patheon brand. With more than 55 locations around the world, we provide integrated, end-to-end capabilities across all phases of development, including API, biologics, viral vectors, cGMP plasmids, formulation, clinical trials solutions, logistics services and commercial manufacturing and packaging. We give pharma and biotech companies of all sizes instant access to a global network of facilities and technical experts across the Americas, Europe, Asia and Australia. Our global leadership is built on a reputation for scientific and technical excellence. We offer integrated drug development and clinical services tailored to fit your drug development journey through our Quick to CareTM program. As a leading pharma services provider, we deliver unrivaled quality, reliability and compliance. Together with our customers, we’re rapidly turning pharmaceutical possibilities into realities.
In APAC, currently we have biologics manufacturing site based in Brisbane, Australia.
In 2022, we will expand our presence in APAC and launch Biologics and Sterile fill finish site in Hangzhou, China and Sterile fill finish site in Singapore.
For more information, please visit our booth.
Peli BioThermal is the first cold chain packaging solutions provider to make available a broad and comprehensive portfolio of patented and award-winning single-use and reusable thermal protection packaging solutions for the safe transport of pharmaceuticals, clinical trials, diagnostics, tissue, vaccines and blood supplies for the life science industry.
Collaboration with our clients is the first step to ensure we provide a solution that is built around the unique and very specific needs of your temperature-sensitive payloads. Our global services network provides consultation, support, engineering and deployment for your cold chain distribution challenges wherever they exist.
Peli BioThermal designs products to ensure our customers valuable payloads are kept in perfect condition, irrespective of external temperatures and conditions. They are designed to be strong and robust, to survive the rigors of international transport. With environmental issues in mind, we ensure that our design team specify the correct materials and consider ‘end of life’ recycling for all of our ranges, whether they are single use or reusable packaging systems.
Marken is a wholly owned subsidiary of UPS and is a critical part of UPS Healthcare. With Polar Speed and Marken included, the UPS Healthcare division staffs 128 locations with 5,500 employees worldwide. Marken offers a state-of-the-art GMP-compliant depot network and logistic hubs for clinical drug product storage and distribution in 59 locations worldwide, while maintaining the leading position for Direct-to-Patient and Home Healthcare services, biological sample shipments and biological kit production.
Marken’s dedicated 2,000 staff members manage 135,000 drug product and biological sample shipments every month at all temperature ranges in more than 220 countries and territories and have orchestrated 11,500+ home healthcare visits. Additional services such as cell and gene supply chain services, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry.
With more than 130 years of experience, Dr. Paul Lohmann® is a German expert in salt manufacturing and provides DPL-BioPharm Salts for the biopharmaceutical industry. These salts act as nutrients for cell cultures, as buffering and post-harvest processing agents within upstream processing. For downstream processing various acetates, citrates, phosphates and sulfates enable efficient bioprocesses for separation, precipitation and purification.
Present your expertise to the key vaccines stakeholders from developing economies through a variety of available speaking packages.
Join the exhibition, and build an impressive presence among your potential clients.
Emphasize on your messages by promoting your brand alongside exhibition and thought leadership.
Engage with and build lasting connections that matter the most to your business.
Gain exclusive access to contacts of high-profile attendees through intimate networking opportunities.